Historical Valuation
Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 25.02 is considered Fairly compared with the five-year average of -10.92. The fair price of Intellia Therapeutics Inc (NTLA) is between 5.46 to 57.34 according to relative valuation methord.
Relative Value
Fair Zone
5.46-57.34
Current Price：10.52
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Intellia Therapeutics Inc (NTLA) has a current Price-to-Book (P/B) ratio of 1.42. Compared to its 3-year average P/B ratio of 2.18 , the current P/B ratio is approximately -34.57% higher. Relative to its 5-year average P/B ratio of 4.68, the current P/B ratio is about -69.58% higher. Intellia Therapeutics Inc (NTLA) has a Forward Free Cash Flow (FCF) yield of approximately -38.68%. Compared to its 3-year average FCF yield of -22.12%, the current FCF yield is approximately 74.86% lower. Relative to its 5-year average FCF yield of -14.85% , the current FCF yield is about 160.48% lower.
P/B
Median3y
2.18
Median5y
4.68
FCF Yield
Median3y
-22.12
Median5y
-14.85
Competitors Valuation Multiple
AI Analysis for NTLA
The average P/S ratio for NTLA competitors is 11.57, providing a benchmark for relative valuation. Intellia Therapeutics Inc Corp (NTLA.O) exhibits a P/S ratio of 25.02, which is 116.19% above the industry average. Given its robust revenue growth of 51.27%, this premium appears sustainable.
Performance Decomposition
AI Analysis for NTLA
1Y
3Y
5Y
Market capitalization of NTLA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NTLA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is NTLA currently overvalued or undervalued?
Intellia Therapeutics Inc (NTLA) is now in the Fair zone, suggesting that its current forward PS ratio of 25.02 is considered Fairly compared with the five-year average of -10.92. The fair price of Intellia Therapeutics Inc (NTLA) is between 5.46 to 57.34 according to relative valuation methord.
What is Intellia Therapeutics Inc (NTLA) fair value?
NTLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Intellia Therapeutics Inc (NTLA) is between 5.46 to 57.34 according to relative valuation methord.
How does NTLA's valuation metrics compare to the industry average?
The average P/S ratio for NTLA's competitors is 11.57, providing a benchmark for relative valuation. Intellia Therapeutics Inc Corp (NTLA) exhibits a P/S ratio of 25.02, which is 116.19% above the industry average. Given its robust revenue growth of 51.27%, this premium appears sustainable.
What is the current P/B ratio for Intellia Therapeutics Inc (NTLA) as of Jan 10 2026?
As of Jan 10 2026, Intellia Therapeutics Inc (NTLA) has a P/B ratio of 1.42. This indicates that the market values NTLA at 1.42 times its book value.
What is the current FCF Yield for Intellia Therapeutics Inc (NTLA) as of Jan 10 2026?
As of Jan 10 2026, Intellia Therapeutics Inc (NTLA) has a FCF Yield of -38.68%. This means that for every dollar of Intellia Therapeutics Inc’s market capitalization, the company generates -38.68 cents in free cash flow.
What is the current Forward P/E ratio for Intellia Therapeutics Inc (NTLA) as of Jan 10 2026?
As of Jan 10 2026, Intellia Therapeutics Inc (NTLA) has a Forward P/E ratio of -2.32. This means the market is willing to pay $-2.32 for every dollar of Intellia Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Intellia Therapeutics Inc (NTLA) as of Jan 10 2026?
As of Jan 10 2026, Intellia Therapeutics Inc (NTLA) has a Forward P/S ratio of 25.02. This means the market is valuing NTLA at $25.02 for every dollar of expected revenue over the next 12 months.